anti-GPC3 CAR T-cell therapy (National Institutes of Health Clinical Center)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-GPC3 CAR T-cell therapy (National Institutes of Health Clinical Center)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Institutes Of Health Clinical Center (Cc)

China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of Health Clinical Center (Cc)

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A